DMRA
Damora Therapeutics, Inc.
-0.06 (-0.24%)24.47USD168K成交股數1.5B市值3.3本益比(近四季)184.9股價營收比+8018.0%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 4.1M+5385% | 3.1M+1246% | 42K-71% | 50K-77% | 74K-71% | 228K-52% | 146K-67% | 213K-51% | 257K | 473K | 442K | 434K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 25.5M | 23.8M | 1.4M | 1.5M | 678K | 1.0M | 1.1M | 1.8M | 2.5M | 2.6M | 8.1M | 10.4M |
| 銷售管理費用 | 9.5M | 7.0M | 1.7M | 2.0M | 1.9M | 1.7M | 2.7M | 2.8M | 3.3M | 3.3M | 3.1M | 3.1M |
| 營業利益 | −35.0M+1246% | −30.8M+334% | −3.2M-18% | −3.4M-39% | −2.6M-55% | −7.1M-17% | −3.8M-66% | −5.6M-59% | −5.7M | −8.6M | −11.2M | −13.5M |
| 營業利益率 | -862.1% | -1,003.6% | -7,514.3% | -6,842.0% | -3,512.2% | -3,114.9% | -2,630.1% | -2,618.3% | -2,233.9% | -1,814.6% | -2,524.7% | -3,108.8% |
| 稅後淨利 | −31.2M+1131% | −27.8M+312% | −3.1M-19% | −3.4M-36% | −2.5M-54% | −6.7M-17% | −3.9M-64% | −5.3M-59% | −5.5M | −8.1M | −10.7M | −13.0M |
| 淨利率 | -768.0% | -905.0% | -7,459.5% | -6,874.0% | -3,423.0% | -2,956.6% | -2,659.6% | -2,506.1% | -2,131.1% | -1,720.1% | -2,430.8% | -2,994.0% |
| 稀釋 EPS | -0.39-80% | -0.62-88% | -2.36-30% | -2.60-47% | -1.92-62% | -5.17-31% | -3.39+727% | -4.92+865% | -5.05 | -7.50 | -0.41 | -0.51 |
| 稀釋股數 | 61.1M | 34.3M | 1.3M | 1.3M | 1.3M | 1.2M | 1.1M | 1.1M | 1.1M | 1.1M | 26.4M | 25.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 541M | 533M | 7.6M | 10.2M | 11.9M | 14.2M | 19.7M | 22.9M | 21.1M | 23.1M | 23.0M | 25.1M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 544M | 535M | 10.7M | 13.7M | 15.4M | 17.1M | 23.4M | 27.3M | 32.5M | 50.0M | 58.8M | 64.6M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 27.6M | 23.8M | 2.7M | 2.7M | 1.7M | 1.3M | 2.4M | 3.7M | 4.3M | 12.7M | 15.1M | 14.3M |
| 股東權益 | 516M | 512M | 8.0M | 11.0M | 13.7M | 15.8M | 20.9M | 23.6M | 28.2M | 37.4M | 43.7M | 50.3M |
| 負債比 | 5.1% | 4.5% | 25.4% | 20.0% | 10.8% | 7.6% | 10.4% | 13.6% | 13.3% | 25.3% | 25.7% | 22.1% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −20.6M | – | – | −2.4M-59% | – | – | – | −5.9M | – | – | −9.1M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 1.2M | +38.3% | −210M | -17,981.1% | 3.98 | – |
| FY2024 | 844K | -50.0% | −21.4M | -2,540.2% | -18.53 | – |
| FY2023 | 1.7M | +133.9% | −38.3M | -2,270.5% | -36.08 | – |
| FY2022 | 722K | +362.8% | −61.6M | -8,535.2% | -2.43 | −43.1M |
| FY2021 | 156K | – | −51.8M | -33,174.4% | -2.05 | −52.5M |
| FY2020 | – | – | −34.8M | –% | -7.62 | – |
| FY2019 | – | – | −36.5M | –% | -161.82 | – |